Aron S Workman

US Patent:

20110294190, Dec 1, 2011

Filed:

Jun 1, 2011

Appl. No.:

13/150676

Inventors:

Aron S. Workman - Gainesville FL, US

International Classification:

C12N 9/02
C12N 5/10
C07H 21/04

US Classification:

435189, 536 232, 435325

Abstract:

The present invention in the art of biochemistry claims novel and non-naturally occurring engineered mutant “human superoxide dismutase 1” (hsod1) variant polypeptides, their encoding nucleic acids, and recombinant cells thereof. The inventor rationally engineered mutant hsod1 variants using structural observations and complimentary experimentation. The engineered mutant hsod1 variant products claimed have multiple potential industrial applications, including as novel therapeutics.

US Patent:

20140377839, Dec 25, 2014

Filed:

Jun 21, 2013

Appl. No.:

13/924451

Inventors:

Aron S. Workman - Gainesville FL, US

International Classification:

C12N 9/02

US Classification:

435189

Abstract:

This invention in biotechnology/bioinformatics claims artificial mutant polypeptides of an oxidoreductase wherein the wild-type (unmutated) oxidoreductase is human catalase (hcat), a superoxide dismutase isoenzyme of superoxide dismutase 2 (hsod2) or superoxide dismutase 3 (hsod3), or a human glutathione peroxidase isoenzyme of human glutathione peroxidase 1 isoform 1 (hgpx1-1), human glutathione peroxidase 1 isoform 2 (hgpx1-2), human glutathione peroxidase 2 (hgpx2), or human glutathione peroxidase 3 (hgpx3). Disclosed in the specification are the methods by which the monoatomic point mutant libraries have been constructed, and the claimed oxidoreductase polypeptides' encoding nucleic acids and recombinant cells thereof. The monoatomic point mutant method generates artificial polypeptides with altered function whilst limiting primary structural obfuscation. The claimed products have multiple potential industrial applications including as novel therapeutics and industrial catalysts.